Objective: The associations between arrest-defective protein 1 (ARD1) gene expression and the clinicopathological characteristics and clinical outcomes of 94 patients undergoing hepatectomy for hepatocellular carcinoma (HCC) were investigated. Methods: ARD1 mRNA levels in HCC and corresponding non-cancerous tissues were quantified by real-time PCR. The gene expression of the tumor relative to that in the non-tumor tissues was calculated using the 2ΔΔCT method. The subjects were classified into high expression (2ΔΔCT > 1, n = 38) and low expression (2ΔΔCT ≤ 1, n = 56) groups. Results: The HCCs did not differ from matched liver tissues in terms of ARD1 mRNA levels. The high expression group had more often microvascular invasion than the low expression group (32 vs. 14%; p = 0.045). The two groups did not differ significantly in terms of other patient or tumor variables. The median follow-up period was 92.1 months. The 5-year recurrence-free and overall survival rates were 34 and 76% for the high expression group, respectively, which were similar to the rates of the low expression group (46 vs. 73%, p = 0.98 and p = 0.52, respectively). Conclusions: Intratumoral ARD1 mRNA overexpression was involved in the microvascular invasion process in patients with HCC, although it did not associate strongly with postresectional outcomes.

1.
Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(suppl 1): S5–S16.
2.
El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557–2576.
3.
Kim DY, Han KH: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2–14.
4.
Valfre di Bonzo L, Novo E, Cannito S, Busletta C, Paternostro C, Povero D, Parola M: Angiogenesis and liver fibrogenesis. Histol Histopathol 2009;24:1323–1341.
5.
Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–364.
6.
Kim KR, Moon HE, Kim KW: Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med (Berl) 2002;80:703–714.
7.
Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000;407:249–257.
8.
Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266–276.
9.
Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL: Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005;105:659–669.
10.
Polevoda B, Sherman F: N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. J Mol Biol 2003;325:595–622.
11.
Kuo HP, Hung MC: Arrest-defective-1 protein (ARD1): tumor suppressor or oncoprotein? Am J Transl Res 2010;2:56–64.
12.
Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, Kim KW: Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 2002;111:709–720.
13.
Bilton R, Mazure N, Trottier E, Hattab M, Dery MA, Richard DE, Pouyssegur J, Brahimi-Horn MC: Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor-1α and is not induced by hypoxia or HIF. J Biol Chem 2005;280:31132–31140.
14.
Brahimi-Horn C, Mazure N, Pouyssegur J: Signalling via the hypoxia-inducible factor-1α requires multiple posttranslational modifications. Cell Signal 2005;17:1–9.
15.
Yu M, Gong J, Ma M, Yang H, Lai J, Wu H, Li L, Tan D: Immunohistochemical analysis of human arrest-defective-1 expressed in cancers in vivo. Oncol Rep 2009;21:909–915.
16.
Arnesen T, Thompson PR, Varhaug JE, Lillehaug JR: The protein acetyltransferase ARD1: a novel cancer drug target? Curr Cancer Drug Targets 2008;8:545–553.
17.
Jiang B, Ren T, Dong B, Qu L, Jin G, Li J, Qu H, Meng L, Liu C, Wu J, et al: Peptide mimic isolated by autoantibody reveals human arrest-defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am J Pathol 2010;177:1095–1103.
18.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2ΔΔCT method. Methods 2001;25:402–408.
19.
Kalvik TV, Arnesen T: Protein N-terminal acetyltransferases in cancer. Oncogene 2012, in press.
20.
Bruix J, Sherman M: Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–1022.
21.
Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, et al: ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Signal 2010;3:ra9.
22.
Midorikawa Y, Tsutsumi S, Taniguchi H, Ishii M, Kobune Y, Kodama T, Makuuchi M, Aburatani H: Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn J Cancer Res 2002;93:636–643.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.